1. Chronic discogenic low back pain — the most advanced program
Mesoblast's rexlemestrocel-L (MPC-06-ID) is an off-the-shelf allogeneic mesenchymal precursor cell therapy delivered by single intradiscal injection. It is the most clinically mature cell therapy anywhere in the world for chronic low back pain associated with degenerative disc disease.
- Phase III (NCT02412735): 404 patients with chronic low back pain ≥6 months refractory to conservative care. Single intradiscal injection of 6 million MPCs vs saline control.
- Outcomes: Statistically significant reductions in pain (VAS) and disability (ODI) vs control that were sustained out to 24–36 months in pre-specified subgroups (chronic pain of shorter duration, no prior interventions).
- Regulatory: Mesoblast has publicly discussed a BLA pathway; FDA has requested additional confirmatory data. No approval yet as of mid-2026.
2. Disc regeneration — DiscGenics IDCT and BioRestorative BRTX-100
DiscGenics IDCT (rebonuputemcel)
Allogeneic discogenic progenitor cells derived from donor intervertebral disc tissue. Single injection into the nucleus pulposus. US Phase II (NCT03347708) and Japan program running in parallel. Reported sustained reductions in low back pain and improved function out to 2 years post-injection, with imaging suggestive of stabilized or modestly improved disc hydration.
BioRestorative Therapies BRTX-100
Autologous, hypoxic-cultured bone marrow-derived MSCs, intradiscally delivered for chronic lumbar disc disease (NCT04042844). Interim Phase II data reported improvements vs baseline in VAS and ODI with a clean safety profile; enrollment ongoing.
3. Exosomes and next-generation biologics
MSC-derived exosomes (extracellular vesicles) are being investigated as a cell-free alternative that delivers the anti-inflammatory and matrix-supportive signaling of stem cells without the cells themselves. Strong preclinical models in disc degeneration; human data remains early — small case series and Phase I feasibility studies, no pivotal trials yet. This is a 2027–2030 timeline, not a today therapy.
4. Safety and regulatory picture
Across the intradiscal MSC/MPC programs to date, safety profiles have been reassuring: no unexpected serious adverse events attributable to the cell product, low rates of injection-site reactions, and no reports of tumorigenesis. The FDA has not yet approved any stem cell therapy for back pain — every program above remains investigational. Patients pursuing unapproved "stem cell injections" at cash-pay clinics are outside this evidence base.
Consolidated status table
| Condition | Lead program | Stage | Headline result |
|---|---|---|---|
| Chronic low back pain (discogenic) | Mesoblast rexlemestrocel-L (MPC-06-ID) | Phase III complete | Pain & function ↓ vs saline at 24–36 mo; BLA path pursued |
| Degenerative disc disease | DiscGenics IDCT (rebonuputemcel) | Phase II (US) | Single injection: sustained pain reduction at 2 yr |
| Lumbar disc degeneration | BRTX-100 (autologous BM-MSC, BioRestorative) | Phase II | Interim: pain & function ↑ vs baseline; safe |
| Cervical / lumbar disc | Kolon TissueGene / Cartistem-derivatives | Phase I/II | Feasibility & early efficacy signals |
| Chronic LBP (adjunct) | MSC-derived exosomes (academic) | Preclinical → early human | Anti-inflammatory signal; no pivotal human data yet |
Bottom line. Rexlemestrocel-L is the closest-to-approval stem cell therapy for chronic back pain, with disc-progenitor programs (IDCT, BRTX-100) behind it and exosome biologics in the wings. No FDA-approved stem cell therapy for back pain exists today. Use this page's AI agent below to pull the latest data on any specific trial or program.